araag2/TREC_Precision-Medicine huggingface dataset:
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer

Summary: Medullary thyroid carcinoma (MTC) is a rare tumor arising from C cells of the thyroid gland and belonging to the endocrine tumors. 18F-DOPA PET, based on tha capacity of endocrine tumor cells to take-up, decarboxylate and store amino-acids, such 3-4-dihydroxyphenylalanine(DOPA), is used for imaging endocrine tumors. The aim of the study was to evaluate the contribution of 18F-DOPA whole-body PET for the detection of recurrences in patients with proven recurrent MTC without evidence of recurrence or metastases on several imaging modalities.

Detailed description: In patients MTC and persistently elevated calcitonin levels, the challenge is finding the site of residual disease. Since the only satisfying treatment is surgery, the early detection and precise location is important. Tumor localization techniques usually performed, including ultrasonography of the neck and liver, chest and abdomen, bone scintigraphy, isotopic scanning and even PET with FDG are poorly sensitive. The use of 18F-DOPA may be more sensitive and specific engineering for localization metastatic disease. The study include 100 patient with persistent MTC demonstrated by elevated tumor markers (calcitonin and CEA) and no evidence of recurrence on morphological imaging procedures. 18F-DOPA whole-body PET is performed 30 minutes after IV injection of 4 MBq/kg of 18F-DOPA, the patient fasted for 6 hours prior the start of the examination.
  All 18F-DOPA PET are evaluated independently by two experienced nuclear medicine physicians and any tracer accumulation exceeding the normal uptake tissue is rated as pathologic finding. The sensibility and efficiency of 18F-DOPA PET will be analysed and Malignant tissue confirmed by histology after surgery or biopsy or by follow-up for one year.

Eligibility: Inclusion criteria:
  -  Patients up to 18 years old with medullary thyroid cancer / carcinoma
  -  Patients with medullary thyroid cancer / carcinoma recurrence, which have a high calcitonin level / rate, more than 100pg/ml, associated - or not - to a high CEA (Carcinoembryonic Antibodies) level / rate, dated from less than 3 months
  -  Patients with a less than 3 months conventional imaging checkup (cervical ultrasonography, cervical-chest-abdomen tomography and / or magnetic resonance imaging, abdomen ultrasonography, osseous / bones radionuclide imaging), in which the tumor site not certainty located
  -  Informed Consent Form signed and dated by patients
  -  Patients which are "SECURITE SOCIALE" affiliated
  Exclusion criteria:
  -  Pregnant or suckling women
  -  Women able to procreate, without efficient birth control
  -  Patients already included in another Nuclear Medicine or Imaging research protocol using ionizing radiations; the efficient dose accumulation will not exceed 20 mSv.

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: Assess Vitamin D Levels in Those With & Without Thyroid Cancer

Summary: The purpose of this study is to evaluate Vitamin D levels in thyroid cancer patients with active disease compared with thyroid cancer patients in remission and patients with thyroid nodules.

Detailed description: Thyroid cancer is the most common endocrine related malignancy, increasing in incidence in recent years. There are relatively few, well known factors, both genetic and environmental, which predispose to the development of thyroid cancer. Vitamin D deficiency has been associated with other cancers, but the association between vitamin D and thyroid cancer is unknown. We plan to do a case control, pilot study to evaluate the relationship between vitamin D levels and thyroid nodules, thyroid cancer in remission, and active thyroid cancer.

Eligibility: Inclusion Criteria:
  -  Cases: History of Papillary, Follicular, Follicular Variant of Papillary, or Hurthle cell thyroid cancer (both active disease and in remission).
  -  Controls: Individuals with a thyroid nodule, matched to cases for age, BMI, season of vitamin D measurement.
  -  Participating in University of Nebraska Medical Center Thyroid Tumor and Cancer Collaborative Registry database.
  Exclusion Criteria:
  -  Pregnant or breast feeding women
  -  Medullary thyroid cancer
  -  Anaplastic thyroid cancer

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)

Summary: This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in papillary renal cell carcinoma. Papillary renal cell carcinoma may be classified into hereditary and sporadic forms; subjects with either classification will be accepted into this study.


Eligibility: Inclusion Criteria:
  -  Histologically confirmed diagnosis of PRC with metastatic disease or bilateral multifocal renal tumors localized to kidneys. Measurable disease, ECOG performance status of </= 2.
  -  Adequate bone marrow reserve, hepatic, renal, and cardiovascular function.
  Exclusion Criteria:
  -  Radiation to >/=25% of bone marrow within 14 days of GSK1363089, more than 1 prior anti-cancer therapy, received prior treatment with a c-met inhibitor, brain metastases,
  -  Any uncontrolled intercurrent illness,
  -  Pregnant or breastfeeding,
  -  HIV positive

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918

Summary: The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD6918 based on the side effects experienced by patients with advanced solid malignancies that receive daily AZD6918 alone. It is possible that AZD6918 will be administered twice daily. Then maximum tolerated doses in combination with either gemcitabine or pemetrexed will also be investigated.


Eligibility: Inclusion Criteria:
  -  Advanced solid tumors for which standard treatment does not exist or is no longer effective.
  -  For chemotherapy combination treatment, must be suitable for treatment with either gemcitabine or pemetrexed.
  -  Relatively good overall health other than cancer.
  Exclusion Criteria:
  -  Poor bone marrow function (not producing enough blood cells).
  -  Poor liver or kidney function.
  -  Serious heart conditions
  -  History of uncontrolled epilepsy, Parkinson's disease, Alzheimer's disease, brain tumor or any uncontrolled psychiatric or nervous system condition

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma

Summary: The purpose of this study is to determine whether the prophylactic ipsilateral central lymph node dissection is equally effective in the management of papillary thyroid microcarcinoma(PTMC) to the bilateral central lymph node dissection.

Detailed description: The extent, the advantage and disadvantage of prophylactic central lymph node dissection was not fully established up to now in papillary thyroid microcarcinoma.
  Prophylactic bilateral central lymph node dissection can give a important clinical information about the status of lymph nodes, and possibly guide a further adjuvant treatment. However, it causes high postoperative morbidity, including hypocalcemia and hoarseness. In this respect, some advocate no central lymph node dissection in prophylactic settings.
  Thus, we aimed to prove the efficacy of prophylactic ipsilateral central lymph node dissection in thyroid papillary microcarcinoma, compared to the bilateral dissection and no dissection.
  Type of Study design: Prospective randomized, controlled double-blinded (to subjects and observers) study.
  Group I: Limited/ipsilateral central lymph node dissection (UniCND) Group II: Comprehensive/bilateral central lymph node dissection (BiCND) Group III: No central lymph node dissection (NoCND)
  Outcomes: vocal cord palsy, hypocalcemia, locoregional recurrence, distant metastasis

Eligibility: Inclusion Criteria:
  -  Age: 18 to 70
  -  Sonographically node-negative cytology confirmed thyroid papillary carcinoma
  -  Tumor size less than 1 cm in sonography
  -  Tumor confined to the one lobe of the thyroid gland
  -  One who provides the informed consent
  Exclusion Criteria:
  -  History of radiation treatment to head and neck area
  -  History of other malignancy except thyroid cancer
  -  Poor performance status (ECOG 3-4)

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer

Summary: This open-label study will assess the efficacy and safety of Avastin with or without pemetrexed as maintenance therapy in patients with advanced, metastatic or recurrent non-small cell lung cancer. In Part 1, patients will receive 4 cycles of treatment with Avastin (7.5mg/kg iv) plus cisplatin (75mg/m2 iv) plus pemetrexed (500mg/m2 iv) on day 1 of each 3-week cycle. In Part 2, patients responding to treatment will be randomized to receive further treatment cycles of Avastin (7.5mg/kg iv every 3 weeks) with or without pemetrexed (500mg/m2 iv every 3 weeks). Anticipated time on study treatment is until disease progression. Target sample size is <500 individuals.


Eligibility: Inclusion Criteria:
  -  adults >/=18 years of age
  -  inoperable, locally advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)
  -  at least 1 measurable lesion meeting RECIST criteria
  -  ECOG performance status 0-2
  -  adequate hematological, liver and renal function
  Exclusion Criteria:
  -  prior chemotherapy or treatment with another systemic anti-cancer agent
  -  malignancies other than NSCLC within 5 years prior to randomization, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer or DCIS
  -  evidence of tumor invading major blood vessels
  -  current or recent use of aspirin (>325mg/day) or full-dose anticoagulants or thrombolytic agents for therapeutic purposes
  -  history of haemoptysis >/=grade 2
  -  clinically significant cardiovascular disease

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) Thyroid

Summary: The purpose of this trial is to see if the 99mTechnetium-MIBI SPECT-CT can be a tool for preoperative evaluation of cervical node metastasis in papillary thyroid cancer.


Eligibility: Inclusion Criteria:
  -  papillary thyroid cancer
  Exclusion Criteria:
  -  pregnancy
  -  Bleeding abnormality
  -  Prior history of head and neck cancer
  -  can not perform 99mTechnetium-MIBI SPECT-CT
  -  can not perform 131I remnant Ablation
  -  Prior any head and neck surgery within 3 months
  -  Prior deep neck infection within 3 months

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: Prophylactic Irradiation of the Para-Aortic Lymph Nodes and Supraclavicular Lymph Nodes in Locally Advanced Uterine Cervical Cancer

Summary: This study is an open-label, randomized study, which is designed to investigate the efficacy of Extended-field irradiation (EFI) on reducing recurrences at the para-aortic lymph node (PAN) and supraclavicular lymph nodes, and also on improving disease-free survival of locally advanced uterine cervical cancer. This study includes a translational research component in that all the primary tumors and lymph node are stained with Sema4c, before randomization. According to the investigators study result, patients with more pelvic lymph node metastasis are more likely to develop distant metastasis including the recurrences at PAN and supraclavicular lymph node. Primary cervical cancer tissues and lymph nodes are examined for expression of Sema4c just after registration, and before the patients are randomized to each arm (pelvis only vs. EFI). The investigators expect a higher benefit of EFI in patients with Sema4c-positive lymph node.


Eligibility: Inclusion Criteria:
  -  Patients (who have been adequately clinically staged) with primary, untreated, histologically confirmed invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix, FIGO stage IB1 with pelvic lymph node metastasis, IB2, IIA(≥4cm in tumor size, or pelvic LN metastasis), IIB, IIIA, IIIB? with only unilateral pelvic wall extension
  -  Patients with negative, para-aortic lymphadenopathy determined by pelvic MRI and/or PET/CT scan.
  -  Patients with adequate bone marrow function: ANC greater than or equal to 1,500/ul, platelets greater than or equal to 100,000/ul at the beginning.
  -  Patients with adequate renal function: creatinine equal to or less than 2.0 mg/dL.
  -  Patients who have signed an approved informed consent and authorization
  -  Patients with ECOG Performance Status of 0, 1, 2 and Karnofsky Performance Scale of 100, 90, 80, 70, 60, 50
  -  Age: 18≤age≤80
  Exclusion Criteria:
  -  Stage IIIb with bilateral pelvic wall extension and stage IVB lesions are not eligible.
  -  Patients with histology other than squamous, adeno, adenosquamous cell carcinoma
  -  Patients who have received prior radiotherapy of pelvis or total hysterectomy Patients who have diagnosis of other malignant tumors other than non-malignant melanoma skin cancer or stage I. II papillary, follicular thyroid cancer.

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)

Summary: In Chronic Renal Failure (CRF) patients with primary glomerular disease or nephrosclerosis as the primary disease:
  -  To confirm the superiority of TRK-100STP over placebo
  -  To determine the recommended therapeutic dose in the 2 doses of TRK-100STP
  -  To assess the safety of TRK-100STP


Eligibility: Inclusion Criteria:
  -  The CRF patient with primary glomerular disease or nephrosclerosis as the primary disease
  -  The patient with progressive CRF
  Exclusion Criteria:
  -  The patient with secondary glomerular disease
  -  The patient with CRF caused by pyelonephritis, interstitial/tubular nephritis, gouty kidney, polycystic kidney disease, or nephroureterolithiasis

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer

Summary: RATIONALE: Collecting and storing samples of tumor tissue and ascites fluid from patients to test in the laboratory may help the study of cancer.
  PURPOSE: This pre-clinical research study is collecting tissue samples and ascites fluid from patients with stage III or stage IV ovarian/primary peritoneal/fallopian tube epithelial cancer.

Detailed description: OBJECTIVES:
  -  To generate a translational ovarian cancer model using tumor tissue and cells from patients with stage III-IV ovarian/primary peritoneal/fallopian tube epithelial cancer for drug response and development.
  OUTLINE: Tissue and fluid samples are collected at the time of surgery or paracentesis and used in laboratory experiments and in animal models. Health data is collected from patient medical records before, during, and after surgery.
  After surgery, patients are followed up for 5 years.

Eligibility: INCLUSION:
  • Females age 18-80 with a diagnosis of Stage III-IV ovarian cancer, primary fallopian tube, or primary peritoneal papillary serous carcinoma and scheduled treatment for epithelial ovarian malignancies.
  EXCLUSION:
  -  Patients with less than Stage III epithelial ovarian cancer, primary fallopian tube, or primary peritoneal papillary serous carcinoma
  -  Patients who have received prior chemotherapy
  -  Patients who have nonepithelial ovarian cancer, primary fallopian tube, or primary peritoneal carcinoma
  -  Patients who have malignancy other than ovarian cancer, primary fallopian tube, or primary peritoneal carcinoma

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: Prophylactic Selective Lateral Neck Dissection in Patients With Papillary Thyroid Carcinoma

Summary: The purpose of this study is to prospectively analyze the incidence of occult lateral neck metastasis (LNM) and to elucidate the factors that predict LNM in papillary thyroid carcinoma (PTC) with central neck metastasis (CNM) by performing prophylactic selective lateral neck dissection (SND).

Detailed description: The lymphatic drainage pattern of the thyroid is uniform and consistent, and therefore, metastatic patterns are relatively predictable. Initial nodal metastasis in PTC usually occurs in the paratracheal and pretracheal nodes in level VI of the central compartment of the ipsilateral neck and spreads to the lateral cervical lymph nodes. Macroscopic skip metastases to the lateral compartment of the neck in the absence of central disease are uncommon.

Eligibility: Inclusion Criteria:
  -  Papillary thyroid carcinoma with central neck metastasis
  -  No evidence of lateral neck metastasis as determined by high-resolution neck ultrasonography and computed tomography
  Exclusion Criteria:
  -  History of previous thyroid operation
  -  Isthmic thyroid lesion

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer

Summary: RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
  PURPOSE: This phase II trial is studying how well everolimus works in treating patients with progressive or recurrent, unresectable, or metastatic thyroid cancer.

Detailed description: OBJECTIVES:
  Primary
  -  To determine the efficacy of everolimus in patients with progressive or recurrent, unresectable, or metastatic differentiated thyroid carcinoma.
  Secondary
  -  To determine maximum percentage of tumor reduction in these patients.
  -  To describe activity time to event endpoints.
  -  To assess toxicity.
  -  To determine evolution of serum thyroglobulin.
  -  To perform explorative pharmacogenomic, pharmacokinetic, and translational studies. (exploratory)
  -  To investigate efficacy of everolimus in patients with progressive or recurrent, unresectable or metastatic disease of undifferentiated (anaplastic) or medullary thyroid cancer.
  OUTLINE: Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Eligibility: DISEASE CHARACTERISTICS:
  -  Diagnosis of thyroid cancer meeting ≥ 1 of the following criteria:
  -  Progressive or recurrent disease
  -  Metastatic disease
  -  Unresectable disease
  -  Meeting any of the following thyroid cancer subtypes:
  -  Differentiated thyroid cancer (i.e., papillary, follicular, or Hurthle cell disease) that is radio-iodine refractory
  -  Undifferentiated thyroid cancer (i.e., anaplastic disease)
  -  Medullary thyroid cancer
  -  Must have received prior everolimus or other mTOR inhibitor therapy
  -  Patients with history of brain metastasis who are neurologically stable following definitive radiation and/or surgery and do not require corticosteroids allowed
  PATIENT CHARACTERISTICS:
  -  Karnofsky performance score 70-100%
  -  ANC ≥ 1,500/mm^³
  -  Platelet count ≥ 100,000/mm³
  -  Hemoglobin ≥ 5.6 mmol/L
  -  Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)
  -  ALT and AST ≤ 2.5 times ULN (≤ 5 times ULN for known liver metastases)
  -  Serum creatinine ≤ 2 times ULN
  -  Negative pregnancy test
  -  No other malignancy, except nonmelanoma skin cancer, carcinoma in situ of the cervix, or a malignancy diagnosed and with no current evidence of malignancy within the past 2 years
  PRIOR CONCURRENT THERAPY:
  -  See Disease Characteristics

Relevance to patient case: not relevant
Patient case: 46-year-old female with papillary thyroid carcinoma; genetic feature: NTRK1

Clinical trial: Comparison of Predictive Factors Related to Coronary Artery Disease Among Different Menopausal Status and Effect of a Life Style Management Program on Risk Factors Modification Among Middle-aged Women

Summary: In Taiwan, heart disease and cerebrovascular disease ranked the second and third of ten leading causes of death in female in 2007; half of these deaths is due to coronary artery disease (CAD). Postmenopausal status is an independent risk factor for CAD. Early assessment and proper management of risk factors may reduce the prevalence rate of CAD. In the past decade, despite increased attention to CAD in women, most studies focused on certain menopausal status instead of all phases of menopause or on risk factors limited to related metabolic syndrome. Because the prevalence of risk factors related to CAD is influenced by various physiological and lifestyle status in different menopausal statuses, the purpose of this study, at the first stage, is to explore respectively the risk factors of CAD among middle-aged women in three menopausal statuses. At the second stage, the influence of a lifestyle management program on risk factors modification among pre-menopausal women is examined in this study.


Eligibility: Inclusion Criteria:
  -  diagnosis of CAD by coroangiography
  -  LVEF >30%
  Exclusion Criteria:
  -  impairment of physical activity
  -  history of psychiatric disorder, vital arrhythmia

Relevance to patient case: not relevant